WBP2 Attenuates Metformin Response in HER2-Positive Breast Cancer Cells by Repressing AMPK Activation and Inducing a Lower AMP:ATP Ratio State Through Enhanced ATP Production

Metformin is an antidiabetic drug that has been tested widely as an anti-cancer agent. However, data from clinical trials have been mixed. Evidence for metformin’s efficacy in HER2+ breast cancer exists. Hence, we evaluated whether WBP2, a HER2-coamplified gene, can regulate the response of HER2+ br...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hexian Lin, Shin-Ae Kang, Fei Xie, Yvonne Xinyi Lim, Sock Hong Seah, Amir Sabbaghian, Ssu-Yi Lu, Ting Gang Chew, Lih-Wen Deng, Shu Wang, E-Shyong Tai, Yoon Pin Lim
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2026-02-01
coleção:	Cells
Assuntos:	WW-domain binding protein 2 metformin HER2-positive breast cancer drug repurposing biomarker
Acesso em linha:	https://www.mdpi.com/2073-4409/15/4/381
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!